| Name | Title | Contact Details |
|---|
Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.
5 PRIME is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Main OfficeReaction Design is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Changing lives with next generation peptide therapeutics